News:

This forum is now live for members so please register and make a difference!

Main Menu

Artificial womb to be developed for premature babies

Started by mensfe_admin, 2019-10-16 09:19

Previous topic - Next topic

mensfe_admin

14 October 2019 - by Bethany Muller
A €2.9m grant has been awarded to a consortium in the Netherlands to fund the development of an artificial womb to support premature babies.
'An artificial womb would be a gamechanger,' said one of the key researchers Professor Guid Oei at Eindhoven University of Technology. 'Our goal with the artificial womb is to help extremely premature babies get through the critical period of 24 to 28 weeks. With each day a fetus of 24 weeks continues to develop in an artificial womb, the chances of survival will increase.'
In 2017, researchers reported growing premature lambs in 'biobags' which supported their ongoing development (see BioNews 898). The consortium plans to make a significant advance on current technologies by creating an artificial womb that more closely resemble conditions in the womb, allowing premature babies to develop to term.
Professor Frans van de Vosse, project coordinator at Eindhoven University, explained: 'Premature babies are placed in a fluid-based environment, just like the natural womb... Oxygen and nutrients are provided via an umbilical cord using an artificial placenta. The system that makes this possible constantly monitors the baby's condition. Think of heart rate and oxygen supply, but also of brain and muscle activity. Smart computer models that simulate the baby's condition provide the doctor with immediate support in the decision-making process with regard to the artificial womb's settings.'
Over the next five years, further research and testing will be carried out to develop the prototype using 3D-printed replicas of human babies and sensors to recreate all aspects of the womb, even down to the maternal heartbeat. 'When they are in this environment, they just feel, and see, and smell, and hear the same sounds as when they are in the womb of the mother,' said Professor Oei.
Elizabeth Chloe Romanis, a lawyer at the University of Manchester who has explored the bioethics of artificial wombs,(see her comment piece in this week's BioNews) warned that the technology could raise questions.
'It is clear that the legal and ethical issues emerging from the technology must be talked about now, in advance of the artificial womb becoming a reality,' she told the Guardian.
Approximately one in 13 UK babies are born prematurely and globally over 1 million babies die each year as a consequence. Those that survive often suffer from organ complications such as chronic lung disease and have an increased risk of disability.
Click here to view SOURCES & REFERENCES and RELATED ARTICLES from the BIONEWS ARCHIVE or to leave a comment about this article.
Mini organs grown from tumours predict patient chemo response
14 October 2019 - by Dr Maria Botcharova
Structures grown from patient's tumour cells can help identify which patients will benefit from chemotherapy drugs, according to a new study.
Scientists at the Netherlands Cancer Institute were investigating the response of metastatic colorectal cancers to the chemotherapy drug irinotecan. Irinotecan can be lifesaving but causes severe side effects including hair loss, diarrhoea and fatigue, and not all patients derive any benefit. The researchers used organoids to predict which cancers would respond to the treatment.
'This means that organoids can help improve decision-making on the best treatment options,' said lead author Salo Ooft.
The researchers hypothesised that if the drug could kill cells in the organoid, this would be a good predictor of success in attacking cancer in the patient. They used cells biopsied from 61 patient tumours to grow the organoids in the lab and were successful in growing these 3D tissue cultures from 35 of the samples.   
After studying the response of the organoids to irinotecan, 80 percent of the predicted patient responses were correct. Importantly, they correctly predicted all the patients who would benefit from the drug.
'The latter is very important as you don't want to deny patients treatment that could have prolonged their life,' said Ooft.
The team's method for developing and screening organoids took only 21 days, compared with two to six months from earlier methodologies.
However, the technique had some limitations. The organoid technique was unsuccessful in predicting the patient's response to a combination therapy consisting of 5-fluorouracil and oxaliplatin. The team believes that this is because factors such as the patient's immune system play a role, which cannot be tested with an organoid.
Click here to view SOURCES & REFERENCES and RELATED ARTICLES from the BIONEWS ARCHIVE or to leave a comment about this article.